Abstract
Overview
Introduction
The neuropathic pain market is forecast to double from 2006 to reach over $7
billion by 2016. At this time, the current late-stage neuropathic pain
pipeline is forecast to take only 18% of the total market share, highlighting
an opportunity for better pipeline drugs that demonstrate improved pain
management. The most promising and closest pipeline drug to market is UCB' s
Vimpat (lacosamide).
Scope
- Analysis of patient potential, unmet needs and clinical trial design in
neuropathic pain
- Overview of drugs in late- and early-stage clinical development; with
analysis of key companies involved in the market
- Detailed profiles of key compounds in development for use in neuropathic
pain, with indication-specific drug sales forecasts to 2016
- Discussion of Pfizer, Eli Lilly and UCB' s market strategies and insight
from key opinion leaders
Highlights
UCB' s increasing CNS portfolio is further bolstered by the imminent arrival of
Vimpat on the market. CNS is a key area of investigation for UCB, constituting
39% of their sales in 2006. UCB has further expanded its reach by trialling
this anticonvulsant not just for epilepsy but also for neuropathic pain,
fibromyalgia, migraine and osteoarthritis.
NeurogesX' s Transacin (capsaicin) treatment is set to cause a stir in the
topical market, currently dominated by Endo' s Lidoderm (lidocaine 5% patch).
The advantageous 3 monthly dosing regimen coupled with a strong efficacy and
safety profile, will see Transacin draw favorable returns in its niche market.
Pfizer will continue to be a major contender in neuropathic pain, with the
current market leader Lyrica predicted to be an even greater commercial
success than its predecessor Neurontin (gabapentin). Pfizer' s branded drugs
are forecast to capture a substantial 41% of the neuropathic pain market share
in 2016.
Reasons to Purchase
- Understand unmet needs in the neuropathic pain market based on key opinion
leader insight
- Benchmark key late-stage neuropathic pain compounds against current market
leaders
- Assess the global (US, Japan, five major EU) sales forecasts of key
late-stage pipeline drugs; and examine their clinical and commercial potential
| 
View Cart
